{"id":"carvedilol-sr-slow-release","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"1-2","effect":"Bronchospasm"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and vasculature. The slow-release formulation provides sustained drug delivery over an extended period, allowing for once-daily dosing. This combination of effects reduces cardiac oxygen demand, lowers blood pressure, and improves cardiac efficiency in heart failure and hypertension.","oneSentence":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:11.707Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Left ventricular dysfunction following myocardial infarction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT05553314","phase":"PHASE4","title":"Carvedilol in HF With Preserved EF","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2021-11-17","conditions":"Heart Failure With Preserved Ejection Fraction, Beta Blocker, Myocardial Strain","enrollment":100},{"nctId":"NCT03209180","phase":"PHASE4","title":"Immediate Release Versus Slow Release Carvedilol in Heart Failure","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2016-10-27","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":320}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CarVeDilol-SR (Slow Release)","genericName":"CarVeDilol-SR (Slow Release)","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}